Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Research and development revenue	$ 1,957,500	$ 397,060	$ 2,678,013	$ 2,212,271
Costs and expenses:
Costs of research and development revenue	395,894	105,869	841,805	1,625,731
Research and development	460,241	716,351	1,498,593	2,444,469
General and administrative	1,297,984	1,282,361	4,694,334	4,164,970
Foreign currency exchange loss	5,995	12,600	14,044	38,143
Total costs and expenses	2,160,114	2,117,181	7,048,776	8,273,313
Loss from operations	(202,614)	(1,720,121)	(4,370,763)	(6,061,042)
Other income (expense):
Interest income	127,331	105,862	353,245	319,787
Gain on sale of Alphazyme	0	0	60,977	1,017,592
Total other income (expense), net	(846)	105,862	112,484	1,337,379
Net loss	$ (203,460)	$ (1,614,259)	$ (4,258,279)	$ (4,723,663)
Basic and diluted net loss per common share (in dollars per share)	$ (0.01)	$ (0.06)	$ (0.15)	$ (0.16)
Basic and diluted weighted-average common shares outstanding (in shares)	29,503,143	28,811,061	29,225,861	28,794,712
Nonrelated Party [Member]
Other income (expense):
Interest expense	$ (88,833)	$ 0	$ (199,106)	$ 0
Related Party [Member]
Other income (expense):
Interest expense	(39,344)	0	(102,632)	0
Research and Development [Member]
Revenues:
Research and development revenue	532,500	352,942	1,253,013	2,079,918
License [Member]
Revenues:
Research and development revenue	$ 1,425,000	$ 44,118	$ 1,425,000	$ 132,353